An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension of the clinical study NLS-1021, evaluating
long-term safety, tolerability, pharmacokinetics (PK), and therapeutic response to treatment
with NLS-2 in adult subjects with narcolepsy.